Prevention

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

Rivaroxaban, a New Oral, Once-Daily Direct Factor Xa Inhibitor,Shows a Significant Reduction in Deep Vein Thrombosis and PulmonaryEmbolism Compared with Enoxaparin with Similarly Low BleedingRates GENEVA, July 8, 2007 - Late-breaking Phase III clinical trialdata presented today at the XXI International Society on Thrombosisand Haemostasis (ISTH) Congress demonstrate that once-daily...

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

GENEVA--(BUSINESS WIRE)--Jul 8, 2007 - Late-breaking Phase IIIclinical trial data presented today at the XXI InternationalSociety on Thrombosis and Haemostasis (ISTH) Congress demonstratethat once-daily rivaroxaban achieved superior efficacy in theprevention of venous thromboembolism (VTE) in patients undergoingknee replacement surgery in a head-to-head comparison withenoxaparin, the curren...

Peer Reviewed Journal Article Indicates Repros' Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jul 5, 2007 - ReprosTherapeutics Inc. (NasdaqGM:RPRX) today announced that an articlehas been published in the July 1, 2007 issue of Oncology Reportsindicating a potential for a new approach to the treatment ofbreast cancer using Proellex. The article reviews the findings froma study conducted in an accepted in vivo rat model of breastcancer. The study...

Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of Blindness in Premature Infants

RICHMOND, Va.--(BUSINESS WIRE)--Jun 26, 2007 - Insmed Incorporated(Nasdaq:INSM), a biopharmaceutical company focused on thedevelopment and approval of drugs for the treatment of metabolicdiseases with unmet medical needs, today noted the publication ofpromising results of research from three universities regarding thepotential role of insulin-like growth factor binding protein-3(IGFBP-3) in...

Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimer's Disease at International Conference on Prevention of Dementia

BROOMFIELD, Colo., June 11, 2007 /PRNewswire/ -- Accera, Inc.today is presenting data from an open-label extension of its PhaseIIb clinical trial of AC-1202 (Ketasyn) in Alzheimer's disease (AD)at the Alzheimer's Association's International Conference onPrevention of Dementia in Washington, D.C. Consistent with thefindings of earlier clinical and preclinical studies, AC-1202 wasshown to...

At the 2007 Alzheimer's Association International Conference on the Prevention of Dementia - Neurochem's U.S. Principal Investigator Presents Update on Tramiprosate (Alzhemed)

WASHINGTON, DC, June 11, 2007 /PRNewswire-FirstCall/ - Paul S.Aisen, M.D., Professor of Neurology and Medicine at GeorgetownUniversity Medical Center, and principal investigator in the UnitedStates of Neurochem Inc.'s North American Phase III clinical trialfor tramiprosate (ALZHEMED(TM)) will present today an update onNeurochem's investigational product candidate for the treatment ofAlzh...

Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine

CHICAGO, IL, Jun 09, 2007 (MARKET WIRE via COMTEX News Network)-- Endo Pharmaceuticals Inc., a wholly owned subsidiary of EndoPharmaceuticals Holdings Inc. (NASDAQ: ENDP), has presented resultsfrom a Phase III randomized, double-blind, placebo-controlledclinical trial evaluating Frova (frovatriptan succinate) 2.5 mgtablets as a six-day preventative treatment in women withdifficult-to-tre...

Investigation Findings, Corroborated by Empirical Evidence of the Schisandra Berry as Cardio-Tonic in Traditional Chinese Medicine for Hundreds of Years, Support the Use of Schisandrin B in the Prevention and Treatment of IHD

SEATTLE--(BUSINESS WIRE)--May 29, 2007 - Mitopharm Corporation,Inc. (Pink Sheets:MTPM), releases the results of a research paperwhere Professor Dr. Robert Ko published the beneficial effects ofSchisandrin B, the precursor of (-) Schisandrin B - a noveldiscovery by Dr. Ko - on Ischemic Heart Disease. In a research paper entitled "SCHISANDRIN B PROTECTS AGAINSTMYOCARDIAL ISCHEMIA-REPERFUSIO...

MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Disease

- Numax Achieves Primary Endpoint Among High-Risk Infants VersusCurrent Standard of Care and Shows Reduction of Medically AttendedOutpatient RSV- Related Lower Respiratory Infections - TORONTO, May 08, 2007 /PRNewswire-FirstCall/ -- MedImmune, Inc.today announced positive results from a large prospective trialconducted for prevention of respiratory syncytial virus (RSV). Thetrial compared...

St. Jude Study Shows Effectiveness of Peramivir in Prevention of Mortality in Mouse Model of Avian Influenza H5N1 Virus Infection

BioCryst Says Study Confirms and Extends Evidence Seen in aPrevious Study BIRMINGHAM, Ala., May 02, 2007 /PRNewswire-FirstCall/ --BioCryst Pharmaceuticals, Inc. today announced that investigatorsat St. Jude Children's Research Hospital, Memphis, TN, reportedfavorable results evaluating peramivir treatment in an animal modelof influenza using a highly virulent strain of H5N1 virus (an avia...

deCODE Announces Positive Topline Results for Phase I Study of DG051 for the Prevention of Heart Attack

REYKJAVIK, Iceland, May 01, 2007 /PRNewswire-FirstCall/ --deCODE genetics today announced positive top-line results from itsPhase I multiple dose clinical trial of DG051, which the company isdeveloping for the prevention of heart attack. In the study, arandomized, double-blind, multi- dose, ascending dose,placebo-controlled clinical trial, a total of 40 healthy subjectswere exposed to DG...

Portola Pharmaceuticals Announces Positive Phase II Results for PRT054021 for Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery

Data to be Presented at the XXI Congress of the InternationalSociety on Thrombosis and Haemostasis SOUTH SAN FRANCISCO, Calif., April 04, 2007 /PRNewswire/ --Portola Pharmaceuticals, Inc. today announced that it has receivedpositive results from EXPERT, a Phase II study of its oral FactorXa inhibitor, PRT054021, for the prevention of venousthromboembolism (VTE) following total knee replac...

Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 8, 2007 - Magen BioSciences,Inc., a specialty dermatology company, today announced thepublication of a paper in the March 9, 2007 issue of the journalCell by its co-founder and board member, David E. Fisher, M.D.,Ph.D., that identifies two new functions for an important protein,p53, in the pigmentation of skin. Fisher's study shows that inaddition to i...